)
Merck (MRK) investor relations material
Merck Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Delivered on 2025 financial guidance with stable net sales at €21.1 billion and organic growth of 3.1%, despite significant foreign exchange and geopolitical headwinds.
EBITDA pre grew to €6.1 billion, up 0.6% reported and 5.6% organically, with margin improvement to 28.9%.
Growth was driven by Process Solutions in Life Science, Rare Diseases and CM&E in Healthcare, and Semiconductor Materials in Electronics.
Strategic acquisitions (SpringWorks, Hub Organoids, JSR Life Sciences chromatography) and divestment of Surface Solutions enhanced the portfolio.
Achieved significant sustainability milestones, including a 60% reduction in Scope 1 and 2 emissions versus 2020.
Financial highlights
FY 2025 net sales were €21.1 billion, down 0.3% year-over-year due to -3.7% FX impact; organic growth of 3.1%.
EBITDA pre was €6.1 billion, up 0.6% reported and 5.6% organically; margin at 28.9%.
EPS pre declined 3.4% to €8.34, mainly due to higher interest costs from USD bond issuance.
Operating cash flow was €3.9 billion, down 14.3% year-over-year.
Net financial debt increased to €8.6 billion, mainly due to the SpringWorks acquisition; leverage at 1.4x net debt/EBITDA pre.
Proposed stable dividend of €2.20 per share, marking 15 consecutive years of stable or increasing dividends.
Outlook and guidance
2026 group net sales forecasted at €20.0–21.1 billion, organic sales development of -1% to +2%.
EBITDA pre guidance for 2026 is €5.5–6.0 billion, organic growth of -4% to +1%, with margins around 28%.
EPS pre expected in the range of €7.10–8.00, assuming no U.S. Mavenclad sales from March 2026 due to generics.
Life Science expected to deliver mid-single-digit organic sales growth, Process Solutions to maintain around 10% growth.
Healthcare faces challenges from key brand life cycles, especially Mavenclad, but expects growth in rare diseases, CM&E, and fertility.
Electronics anticipates continued strong growth in Semiconductor Materials and stabilization in DS&S.
- 2025 guidance met with stable sales and EBITDA; 2026 outlook cautious amid FX and Mavenclad risks.MRK
Q4 2025 (Media)5 Mar 2026 - Q2 2024 growth led by Healthcare and Electronics, with raised guidance for the full year.MRK
Q2 202412 Feb 2026 - Q3 2024 delivered strong organic growth, margin expansion, and confirmed 2024 guidance.MRK
Q3 202412 Feb 2026 - Q1 2025 delivered solid growth and margin expansion, with guidance reflecting macro headwinds.MRK
Q1 202512 Feb 2026 - Life Science and Healthcare growth drove Q2 2025 organic gains, offsetting Electronics and FX headwinds.MRK
Q2 202512 Feb 2026 - Q3 2025 saw robust organic growth, margin gains, and strategic expansion amid FX risks.MRK
Q3 202512 Feb 2026 - Promising DDR and ADC assets advance in clinic, with strong external partnerships and biomarker focus.MRK
Investor Update31 Jan 2026 - All sectors on track for sustainable growth, margin expansion, and ESG leadership.MRK
CMD 202419 Jan 2026 - Growth led by Process Solutions, rare diseases, and semiconductors, with margin expansion targeted.MRK
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026
Next Merck earnings date
Next Merck earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)